Active Biotech's election committee appointed

Active Biotech's election committee appointed

ID: 7949

(Thomson Reuters ONE) - In accordance with a decision made by the Annual General Meeting heldon May 7, 2009, the Election Committee shall comprise therepresentatives for the three largest shareholders on September 30and the Board Chairman.For the 2010 Annual General Meeting, the Election Committee shallpropose Board members and a Board Chairman, and fees to Board membersand auditors. The following individuals were appointedrepresentatives for the largest shareholders and, accordingly, aremembers of the Election Committee:Johnny Sommarlund, MGA HoldingTomas Billing, NordstjernanPeter Thelin, Brummer & PartnersUnder the leadership of the Board Chairman Mats Arnhög, the ElectionCommittee shall prepare proposals for the Board of Directors that areto be presented to and decided upon at the Annual General Meeting onMay 6, 2010.Lund, November 5, 2009Active Biotech AB (publ)Tomas LeandersonPresident and CEOAbout Active BiotechActive Biotech AB (NASDAQ OMX NORDIC: ACTI) is a biotechnologycompany with focus on autoimmune/inflammatory diseases and cancer.Projects in pivotal phase are laquinimod, an orally administeredsmall molecule with unique immunomodulatory properties for thetreatment of multiple sclerosis, as well as ANYARA for use in cancertargeted therapy, primarily of renal cancer. Further key projects inclinical development comprise the three orally administered compoundsTASQ for prostate cancer, 57-57 for SLE and RhuDex(TM) for RA. Pleasevisit www.activebiotech.com for more information.Active Biotech is obligated to publish the information contained inthis press release in accordance with the Swedish Securities MarketAct. This information was provided to the media for publication onNovember 5, 2009 at 8:30 a.m.Active Biotech ABPO Box 724, SE-220 07 LundSwedenTel: +46 (0)46-19 20 00Fax: +46 (0)46-19 11 00www.activebiotech.comThis announcement was originally distributed by Hugin. The issuer is solely responsible for the content of this announcement.



Unternehmensinformation / Kurzprofil:
drucken  als PDF  an Freund senden  Active Biotech AB Interim Report, January - September 2009 BÿWE Group achieves significant progress in debt reduction in the
third quarter 2009
Bereitgestellt von Benutzer: hugin
Datum: 05.11.2009 - 08:32 Uhr
Sprache: Deutsch
News-ID 7949
Anzahl Zeichen: 0

contact information:
Town:

London



Kategorie:

Business News



Diese Pressemitteilung wurde bisher 370 mal aufgerufen.


Die Pressemitteilung mit dem Titel:
"Active Biotech's election committee appointed"
steht unter der journalistisch-redaktionellen Verantwortung von

Active Biotech (Nachricht senden)

Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).

Active Biotech AB Interim Report, January - September 2009 ...

* Laquinimod -- new data presented at ECTRIMS * 57-57 -- exploratory clinical trial in progress * RhuDex(TM) -- clinical development to continue following feedback from UK MHRA * ANYARA -- complete Phase I data published * TASQ -- complete Phase I ...

Alle Meldungen von Active Biotech



 

Werbung



Facebook

Sponsoren

foodir.org The food directory für Deutschland
Informationen für Feinsnacker finden Sie hier.

Firmenverzeichniss

Firmen die firmenpresse für ihre Pressearbeit erfolgreich nutzen
1 2 3 4 5 6 7 8 9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z